Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Heart Failure Enrolled in a Managed Care Organization: Effect on Costs and Probability of Hospitalization

Pharmacotherapy

Volumn 24, Issue 3, 2004, Pages 351-357

  Abarca, Jacob ^a,b   Malone, Daniel C ^a   Armstrong, Edward P ^a   Zachry III, Woodie M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Heart failure; Managed care organization; Retrospective studies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DEMOGRAPHY; DRUG EFFECT; FEMALE; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; REGRESSION ANALYSIS; REIMBURSEMENT; RESOURCE MANAGEMENT; RISK ASSESSMENT;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 1542346487     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.4.351.33175     Document Type: Article

References (31)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Dallas, TX: American Heart Association, 200:1-56.
2. American Heart Association. Heart disease and stroke statistics: 2003 update. Dallas, TX: American Heart Association, 2002.
3. Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitalization of patients with heart failure: national hospital discharge survey, 1985 to 1995. Am Heart J 1999;137(2): 352-60.
4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45(8):968-74.
5. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985;55(2):3A-8.
6. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol 1993;22(4 suppl A):6A-13.
7. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133(6):703-12.
8. Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure: on behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83(2A):1A-38.
9. Heart Failure Society of America (HFSA). HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: pharmacological approaches. J Cardiac Failure 1999;5(4):357-82.
10. Munger MA, Cheang KI. β-Blocker therapy: a standard of care for heart failure. Pharmacotherapy 2000;20(11 pt 2): 359S-67.
11. Paul SD, Kuntz KM, Eagle KA, Weinstein MC. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994;154(10):1143-9.
12. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the studies of left ventricular dysfunction (SOLVD) treatment trial. J Cardiac Fail 1995;1:371-80.
13. Roe CM, Motheral BR, Teitelbaum F, Rich MW. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure. Am Heart J 1999;138(5 pt 1):818-25.
14. Cohn JN, Fowler MB, Bristow MR, et al. Safety and efficacy of carvedilol in severe heart failure: the U.S. carvedilol heart failure study group. J Cardiac Fail 1997;3 (3):173-9.
15. Barron HV, Michaels AD, Maynard C, Every NR. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. J Am Coll Cardiol 1998;32(2):360-7.
16. Rathore SS, Foody JM, Wang Y, et al. Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA 2003;289(19):2517-24.
17. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45(2):197-203.
18. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325(5):293-302.
19. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327(10):685-91.
20. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 1992;327(10): 669-77.
21. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988;259(4):539-44.
22. Goff DC Jr, Pandey DK, Chan FA, Ortiz C, Nichaman MZ. Congestive heart failure in the United States. Is there more than meets the I(CD code)? The Corpus Christi heart project. Arch Intern Med 2000;160(2):197-202.
23. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26(7):1565-74.
24. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46(2):328-46.
25. Konstam M, Dracup K, Baker D, et al. Heart failure: management of patients with left ventricular systolic dysfunction. Quick reference guide for clinicians, no 11, AHCPR publication no. 94-0613. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, June 1994.
26. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure: ATLAS (assessment of treatment with lisinopril and survival) study group. Circulation 1999;100(23):2312-18.
27. Schwartz JS, Wang YR, Cleland JG, et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the assessment of treatment with lisinopril and survival (ATLAS) trial. Am J Manag Care 2003;9(6):417-24.
28. Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther 1997;19(2):346-66.
29. Arnold RG, Kotsanos JG, Motheral BR, et al. Methodological issues in conducting pharmacoeconomic evaluations: retrospective and claims database studies. Value in Health 1999;2(2):82-7.
30. Cook TD, Campbell DT. Quasi-experimentation: design and analysis issues for field settings. Boston, MA: Houghton Mifflin, 1979.
31. Polanczyk CA, Rohde LE, Philbin EA, Di Salvo TG. A new case mix adjustment index for hospital mortality among patients with congestive heart failure. Med Care 1998;36(10):1489-99.